PT2205721T - Células tr1, células-tronco mesenquimais e usos das mesmas - Google Patents

Células tr1, células-tronco mesenquimais e usos das mesmas

Info

Publication number
PT2205721T
PT2205721T PT88403589T PT08840358T PT2205721T PT 2205721 T PT2205721 T PT 2205721T PT 88403589 T PT88403589 T PT 88403589T PT 08840358 T PT08840358 T PT 08840358T PT 2205721 T PT2205721 T PT 2205721T
Authority
PT
Portugal
Prior art keywords
cells
mesenchymal stem
stem cells
mesenchymal
stem
Prior art date
Application number
PT88403589T
Other languages
English (en)
Inventor
Foussat Arnaud
Belmonte Nathalie
Original Assignee
Txcell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Txcell filed Critical Txcell
Publication of PT2205721T publication Critical patent/PT2205721T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/462Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/46433Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662Stem cells
    • C12N5/0667Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
PT88403589T 2007-10-17 2008-10-17 Células tr1, células-tronco mesenquimais e usos das mesmas PT2205721T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98054107P 2007-10-17 2007-10-17

Publications (1)

Publication Number Publication Date
PT2205721T true PT2205721T (pt) 2016-10-11

Family

ID=40292511

Family Applications (1)

Application Number Title Priority Date Filing Date
PT88403589T PT2205721T (pt) 2007-10-17 2008-10-17 Células tr1, células-tronco mesenquimais e usos das mesmas

Country Status (12)

Country Link
US (1) US20100247577A1 (pt)
EP (2) EP3109317A1 (pt)
JP (1) JP5539886B2 (pt)
KR (2) KR20100076031A (pt)
CN (1) CN101835889B (pt)
AU (1) AU2008313693B2 (pt)
CA (1) CA2702572A1 (pt)
DK (1) DK2205721T3 (pt)
ES (1) ES2595103T3 (pt)
PT (1) PT2205721T (pt)
RU (1) RU2493869C2 (pt)
WO (1) WO2009050282A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
EP2062970A1 (en) * 2007-11-26 2009-05-27 Txcell Compositions for treating an intestinal inflammatory condition
EP2439534A1 (en) * 2010-10-08 2012-04-11 TXCell Method for assessing the efficacy of a TR1 cell therapy in asubject
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
WO2013125899A1 (ko) * 2012-02-22 2013-08-29 주식회사 강스템홀딩스 줄기세포를 유효 성분으로 함유하는 면역 질환 또는 염증 질환의 예방 또는 치료용 조성물
US10028979B2 (en) * 2012-12-12 2018-07-24 Mesoblast, Inc. Methods of treating or preventing respiratory conditions
US10251934B2 (en) 2013-04-16 2019-04-09 Orbsen Therapeutics Limited Syndecan-2 compositions and methods of use
WO2014207679A1 (en) * 2013-06-25 2014-12-31 Tigenix S.A.U. Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
EP3047275B1 (en) 2013-09-06 2020-11-18 Consejo Nacional De Investigaciones Cientificas Y Tecnicas Compositions and methods for increasing mesenchymal stromal cell migration to tumors
WO2016048052A1 (ko) * 2014-09-25 2016-03-31 주식회사 강스템바이오텍 비만세포 과립을 처리한 줄기세포 또는 그 배양물을 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약학조성물
WO2016150884A1 (en) 2015-03-20 2016-09-29 Orbsen Therapeutics Limited Modulators of syndecan-2 and uses thereof
CA2983950A1 (en) * 2015-04-24 2016-10-27 Tigenix S.A.U. Biomarkers for determining the clinical response to cell therapy
EP3922253A1 (en) 2016-01-15 2021-12-15 Orbsen Therapeutics Limited Sdc-2 exosome compositions and methods of isolation and use
RU2727900C2 (ru) * 2016-02-26 2020-07-24 ЭсСиЭм ЛАЙФСАЙЕНС КО., ЛТД. Фармацевтическая композиция для предотвращения или лечения заболеваний, опосредованных регуляторными т-клетками
GB201604304D0 (en) 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
JP6152205B1 (ja) * 2016-08-09 2017-06-21 仁幸 小林 化粧品、医薬用組成物、およびそれらの製造方法
CN106265899A (zh) * 2016-09-30 2017-01-04 广州赛莱拉干细胞科技股份有限公司 一种组合物及其在制备改善慢性鼻炎的产品中的应用
EP3652305A2 (en) 2017-07-14 2020-05-20 Orbsen Therapeutics Limited Cd39 stromal stem cells methods of isolation and use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6149906A (en) * 1997-09-20 2000-11-21 Osiris Therapeutics, Inc. Antigen presenting cells of the adipocyte lineage
US6368636B1 (en) * 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
WO1999051275A2 (en) 1998-04-03 1999-10-14 Osiris Therapeutics, Inc. Mesenchymal stem cells as immunosuppressants
US6685936B2 (en) 1999-10-12 2004-02-03 Osiris Therapeutics, Inc. Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
US6746670B2 (en) 2000-08-15 2004-06-08 Schering Corporation Regulatory T cells; methods
FR2824567B1 (fr) * 2001-05-11 2003-08-08 Inst Nat Sante Rech Med Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
FR2856700B1 (fr) * 2003-06-24 2007-06-08 Txcell Procede d'identification de lymphocytes tr1 regulateurs par la presence et la surexpression de molecules specifiques et ses applications
US20070009497A1 (en) 2004-03-10 2007-01-11 Steinman Ralph M Dendritic cell expanded T suppressor cells and methods of use thereof
EP2824174B1 (en) 2004-03-22 2018-11-28 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
US7985409B2 (en) * 2004-08-11 2011-07-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Tr1 cells for use in atherosclerosis
GB0503936D0 (en) 2005-02-25 2005-04-06 San Raffaele Centro Fond Method
SI1739166T1 (sl) 2005-07-01 2011-11-30 Txcell S A PRIDOBIVANJE CELIC Tr1 SPECIFIČNIH ZA ALIMENTARNI ANTIGEN ALI AVTOGEN IZ LEVKOCITNE ALI PBMC POPULACIJE
EP2185689A2 (en) * 2007-08-09 2010-05-19 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells

Also Published As

Publication number Publication date
CN101835889B (zh) 2013-07-17
KR20160003307A (ko) 2016-01-08
KR20100076031A (ko) 2010-07-05
EP2205721A1 (en) 2010-07-14
CA2702572A1 (en) 2009-04-23
RU2493869C2 (ru) 2013-09-27
WO2009050282A1 (en) 2009-04-23
JP5539886B2 (ja) 2014-07-02
ES2595103T3 (es) 2016-12-27
AU2008313693A1 (en) 2009-04-23
EP3109317A1 (en) 2016-12-28
RU2010119515A (ru) 2011-11-27
DK2205721T3 (en) 2016-10-24
EP2205721B1 (en) 2016-07-13
AU2008313693B2 (en) 2014-04-24
US20100247577A1 (en) 2010-09-30
JP2011500045A (ja) 2011-01-06
CN101835889A (zh) 2010-09-15

Similar Documents

Publication Publication Date Title
PT2205721T (pt) Células tr1, células-tronco mesenquimais e usos das mesmas
HK1216883A1 (zh) 幹細胞培養
GB2434691B8 (en) Fuel cell.
PL2046946T3 (pl) Hodowla pluripotencjalnych komórek macierzystych
IL197444A0 (en) Cell culture improvements
PL2254586T3 (pl) Cząstki mezenchymalnych komórek macierzystych
SI2772535T1 (sl) ABC5 pozitivne mezenhimske matične celice kot imunomodulatorji
EP2315829A4 (en) INDUCED PLURIPOTENT STEM CELLS
ZA201000715B (en) Single pluripotent stem cell culture
EP2007411A4 (en) REGULATORY STEM CELLS
HK1147218A1 (en) Stem cell lines, their application and culture methods
EP2118278A4 (en) TARGETED GENE MODIFICATION OF STEM CELLS
IL211994A0 (en) Prostate stem cells and uses thereof
EP2294182A4 (en) CULTS OF MULTIPOTENT STEM CELLS
GB0606671D0 (en) Cell Culture
GB0817240D0 (en) Modified bacterial cell
GB0818256D0 (en) stem cells
GB2467284B (en) Sulfatase enzymes
GB0724994D0 (en) Mesenchymal stem cell markers
GB0602208D0 (en) Embryonic stem cells
IL193947A0 (en) Regulating stem cells
GB0625041D0 (en) Prostate stem cell model
GB0500869D0 (en) Stem cells
GB0602082D0 (en) Cells
AU2006902280A0 (en) Stem cells